This product is not available for sale in your country. Please feel free to contact the help desk if you have any questions.
|Country Availability||DK, EE, FI, FO, GL, IS, LT, LV, NO, SE|
|Data Sheet Link||https://www.mblintl.com/assets/rn0019m-v1.pdf|
|Description||Anti-2,2,7-trimethylguanosine (m3G/TMG) mAb|
|Supplier||MBL International Corp.|
|Notes||Small nuclear RNA (snRNA) is known to be involved in pre-mRNA splicing as an RNA component of snRNP. 2,2,7-trimethylated guanosine (m3G/TMG) is a modified nucleoside at the 5’-cap site of U snRNAs except for U6 snRNA. Shortly after transcription, 7-methylguanosine (m7G), called cap structure, is added to 5’-end of <a>newly</a> synthesized U snRNA and m7G-capped U snRNA is exported to the cytoplasm. The m7G-cap is converted to m3G-cap, which is a hypermethylated structure of 5’-end, by cytoplasmic catalytic protein TSG1 and the m3G-capped U snRNA forms snRNP with Sm proteins in the cytoplasm, followed by entry into the nucleus. The m3G-capped snRNP plays a role in regulation of pre-mRNA splicing as a part of spliceosome in nucleus. <a>It is also reported that</a> U3 and U8 snoRNA, localized to Cajal body during RNP biogenesis, possess m3G-cap structure.|
|Alias Names||N2,N2,7-Trimethylguanosine, m2,2,7G|
|Source / Host||mouse|
|Substrate / Buffer||1 mg/mL in PBS/50% glycerol, pH 7.2|
|Product Page Updated||2019-01-15T09:09:13.918Z|
The delivery time for this item is approximately 5-8 business days. If other deviations occur, this will be noted on the order confirmation or communicated via email. Please note, we do reserve the right to select the best packaging and shipping method in order to insure the stability of the product and allow efficient order tracking.